Results 21 to 30 of about 76,984 (297)

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. [PDF]

PLoS ONE, 2015
BACKGROUND AND OBJECTIVE:The association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial.
Wei-Long Shi, Hui-Lin Tang, Suo-Di Zhai
doaj   +1 more source

Case Report: Acute Pancreatitis Associated With Tacrolimus in Kidney Transplantation and a Review of the Literature

Frontiers in Medicine, 2022
BackgroundDrug-induced pancreatitis is a rare cause of acute pancreatitis. Tacrolimus has been used as an immunosuppressant agent in patients after organ transplantation. However, only a few case reports of tacrolimus-induced acute pancreatitis in kidney
Yixuan Ding, Yixuan Ding, Chang Qu, Chang Qu, Huan He, Feng Cao, Feng Cao, Tongwen Ou, Fei Li, Fei Li   +9 more
doaj   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Comparative Study of the Cellular Pharmacodynamics of Tacrolimus in Renal Transplant Recipients Treated with and without Basiliximab

Cell Transplantation, 2012
Basiliximab is a recently developed immunosuppressive agent for the prevention of acute allograft rejection in renal transplant recipients. The combination use of basiliximab and a calcineurin inhibitor was suggested to be more effective in comparison to
Kentaro Sugiyama Ph.D., Kazuya Isogai, Satoshi Horisawa, Akira Toyama, Hiroshi Satoh, Kazuhide Saito, Yuki Nakagawa, Masayuki Tasaki, Kota Takahashi, Toshihiko Hirano   +9 more
doaj   +1 more source

A case report: acute pancreatitis associated with tacrolimus in kidney transplantation

BMC Nephrology, 2019
Background Tacrolimus has been widely used for immunosuppressive therapy in solid organ transplantation (SOT) and allo-geneic stem cell transplantation (allo-SCT) over the past 2 decades.
Junnan Xu, Liang Xu, Xing Wei, Xiang Li, Ming Cai   +4 more
doaj   +1 more source

Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?

Pharmaceutics, 2021
Tacrolimus presents high intra and inter-individual variability in its blood trough concentration (Cmin). Knowledge of the factors that are involved in tacrolimus Cmin variability is thus clinically important to prevent or limit it.
Anaelle Chavant, Xavier Fonrose, Elodie Gautier-Veyret, Marie Noelle Hilleret, Matthieu Roustit, Francoise Stanke-Labesque   +5 more
doaj   +1 more source

Tacrolimus as Antifungal Agent

Acta Chimica Slovenica, 2019
Tacrolimus (FK506) is an immunosuppressant drug widely used to avoid organ rejection in transplant patients. It has a profound influence on the cellular stress response by interfering with the calmodulin-calcineurin signaling pathway. In this context FK506 also became a valuable antifungal drug in medical care. Here it is shown in vitro that tacrolimus
Fatuma Meyer, Leif-Alexander Garbe, Zhanar Sadykova, Lyudmyla M. Antypenko, Karl G. Steffens   +4 more
openaire   +5 more sources

Tacrolimus for the Treatment of Ulcerative Colitis [PDF]

Intestinal Research, 2015
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients ...
Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe   +7 more
doaj   +1 more source

Exploring patients’ profiles associated with the resolution of acute calcium pyrophosphate arthritis treatedwith colchicine and prednisone: post hoc analysis of a randomized controlled trial

Arthritis Care &Research, Accepted Article.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne‐France Georgel, Augustin Latourte, Hang‐Korng Ea, Sébastien Ottaviani, Charlotte Jauffret, Vincent Ducoulombier   +14 more
wiley   +1 more source

Suplatast/Tacrolimus Combination Therapy for Refractory Facial Erythema in Adult Patients with Atopic Dermatitis—A Meta-Analysis Study—

Allergology International, 2007
Background: Combination of suplatast tosilate with tacrolimus ointment was reported to reduce the dose of tacrolimus ointment with maintained treatment efficacy for refractory facial erythema in atopic dermatitis (AD), however these were only case ...
Yoshiki Miyachi, Ichiro Katayama, Masutaka Furue   +2 more
doaj   +1 more source